anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Tumor budding is a phenomenon in which the tumor cells detach from the main mass and are present at the invasive front. The present study was conducted to study tumor budding in invasive breast carcinoma and to correlate it with clinicopathological parameters and molecular subtypes.
METHODS: The study was conducted over a period of 1 year, and tumor budding was studied as a single or group of cells at the invasive front of breast carcinoma counted in a high-power field (40×). The grading was statistically correlated with tumor size, grade, lymph node status, lymphovascular invasion, pathological TNM staging, molecular subtype, and survival of patients.
RESULTS: A total of 50 cases of invasive breast carcinoma were included, out of which 66% (n=33) showed high-grade tumor budding, which was statistically significantly higher in grade 2 invasive ductal carcinoma (p<0.05). High tumor budding was associated with lymphovascular invasion, lymph node metastasis, and a high Ki-67 proliferative index. All cases showing low-grade budding were alive until 6 months of diagnosis, but there was no statistically significant association between stage and budding.
CONCLUSION: Tumor buds are significantly higher in grade 2 invasive ductal carcinoma with lymphovascular invasion, lymph node metastasis, and a high Ki-67 proliferative index. Immunohistochemistry may prove helpful in distinguishing tumor buds from their mimickers. Further studies with extended follow-up are recommended to predict tumor budding as a prognostic marker in breast carcinoma, which may play an important role in cancer therapy.
A method and system for leading macromolecule substances into target cells includes an image picking unit, an image merging unit, an injection unit, and an energy conversion module. The image picking unit is used for picking up the three-dimensional (3D) and the 3D blood vessel photographic images of the tissue or organ where the target cells locate. The image merging unit is used for merging the 3D structure images into the 3D blood vessel photographic images, therefore choosing a blood vessel passage fully covering the target cells for transmitting the macromolecule substances. The injection unit is used for injecting liquid and transmitting the macromolecule substances to the target cells. The energy conversion module is used for exerting energy to activate the liquid to perform biological effects, thereby forming non-permanent holes in the cell membranes of the target cells. The macromolecule substances enter into the target cells through the non-permanent holes.
This invention provides an isolated nucleic acid molecule encoding a protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells. The nucleic acid molecule may include a DNA molecule or a cDNA molecule. This invention further provides a gene transfer vector including the nucleic acid molecule operably linked to a promoter of RNA transcription. The vector may be a plasmid or a viral vector. This invention further provides a host vector system including the gene transfer vector in a suitable host cell. The transformed yeast or a stably transformed mammalian cell. This invention further provides a method of producing a T cell surface protein necessary for T cell activation of B cells which includes growing the host vector system under conditions permitting production of the protein, followed by recovering the protein so produced. This invention further provides for methods to inhibit humoral immune responses, immunoglobulin production and B cell activation with 5C8-specific antibodies.
Patients receive ibrutinib PO and obinutuzumab as in arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and CT scans before and after treatment and collection of blood throughout the study.
A method for preparing hyperimmune diagnostic serum against Aujeszky's disease virus comprises the collection of the raw material, namely the stock of the antigen of Aujeszky's disease virus, virus inactivation, mixing with oil adjuvant, immunization of the animals, blood collection and assay for specific humoral antibodies in the reaction of neutralization. The female goats are used for immunization with Petrikivskyi-2006 strain of Aujeszky's disease virus. The oil adjuvant Montanide ISA 25 is mixed with the antigen in 3:1 ratio. The animals are immunized intramuscularly nine times. The second immunization follows in 21 days after the primary one, and then the immunizations follow in every 7 days. 200-300 mL of the blood is collected from the jugular vein. The titer of the specific antibodies should be at the level of 10.5±0.12 log2 in the reaction of neutralization while assayed on transplantable cell line of porcine testicles.
The present invention provides a traditional Chinese medicine technology for bleaching and dispelling chorioplaque by oral administration and external use. The chorioplaque is cured by the oral administration and the external use of the traditional Chinese medicine. External use medicine is paste which is formed by matching raw materials of a denudation substance, titanium dioxide, micronasole, etc. Oral administration medicine is composed of raw materials of liquorice, fructus corni, tuckahoe, angelica, dahurian angelica, etc. The traditional Chinese medicine can be used for dispelling the chorioplaque, and a low-grade patient can be cured in a month, and a severe patient can be cured in six months. The cure rate can reach 100%, and the chorioplaque does not relapse.
Diagnostic overshadowing is a bias in which symptoms of a psychological disorder are falsely attributed to a known diagnosis of intellectual disability. This systematic review evaluated all research on diagnostic overshadowing conducted to date, including dissertations and peer-reviewed journal articles. In total, 25 studies were included in this review. Findings suggest diagnostic overshadowing may not be as ubiquitous as originally believed, with one third of included studies finding no overshadowing. The quality of the evidence was graded as "Low" using the LEGEND tool, with common issues including outdated studies, analogue methodologies, small sample sizes and convenience samples, and inappropriate conducting or reporting of statistical analyses. Implications for the field and recommendations for future research are discussed.
H. pylori was one of the most important carcinogenic factor for gastric cancer and play a crucial role in inducing gastritis, atrophy and canceration. Chronic atrophic gastritis (CAG) was a common precancerous disease, people with CAG become high-risk population and need regular follow-up. However, study about occurrence risk prediction for gastric cancer when H. pylori infection concurrence with CAG was still spare. In especial, there was still no population screening program based on serology. The relative clinical epidemiology for providing evidence for China gastric cancer screening program was very rare.

This study aim to evaluate gastric cancer occurrence risk and diagnostic value of people combined with H. pylori infection and CAG by Serological methods in Sichuan province China. We also project to design optimized screening program suitable for people in sichuan province China.
Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
Combination of Protease Inhibitors

Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin calcium with several combinations of protease inhibitors [see Clinical Pharmacology (12.3)].  In patients taking tipranavir plus ritonavir or glecaprevir plus pibrentasvir, concomitant use of atorvastatin calcium should be avoided. In patients taking lopinavir plus ritonavir, or simeprevir, use the lowest necessary atorvastatin calcium dose. In patients taking saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, or elbasvir plus grazoprevir, the dose of atorvastatin calcium should not exceed 20 mg. In patients taking nelfinavir the dose of atorvastatin calcium should not exceed 40 mg and close clinical monitoring is recommended. [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)].
Baseline assessment will be followed by randomisation and dose introduction. Patients will be randomly assigned to two counterbalanced groups starting either with Sativex or with placebo as the first drug. They will be dispensed sufficient study medication for two weeks together with a diary. During the two-week treatment period all the patients will have to be reached the optimal, individualised dosage to subjectively relief spasticity.Patient will return after three weeks and they will undergo the fMRI and neurophysiological evaluations.Then patients will perform a two-week washout period and they will be requested to intake the alternative medicine. After two weeks patients will perform a second fMRI/neurophysiological study. Two weeks later, after a second washout period, a last visit will be performed to conclude the study.
PURPOSE:To obtain an organic material fine particle having high level sphericity, that is, a shape near true sphere, without receiving large heat history by suspending an organic material powder having a specific particle size in an organic solvent such as petroleum hydrocarbon and granulating in liquid with a specific ratio of water or the like as a binder. CONSTITUTION:The organic material powder (e.g. anhydrous lactose powder) having the particle size constitution of 500mum max. particle diameter is granulated in liquid in a granulator 7 by suspending in the organic solvent of the petroleum hydrocarbon or a halogenated hydrocarbon and using water or a liquid made by mixing water with a high molecular material (e.g. polyvinyl alcohol) as the binder so that the quantity of the binder to be used is 5-25wt.% per the organic material powder. As a result, the organic material fine particle having high level sphericity, that is, the shape near true sphere, is obtained without receiving large heat history. The particle size of the obtained particle is adjusted by controlling the quantity of the binder or the stirring speed.
Behavioral Activation (BA) is a psychotherapy modality that can be used to treat depression. The 60 minute session of BA is designed to actively engage with the client in creating personalized goals and ways in which maladaptive coping mechanisms maintaining depression can be addressed and replaced with increased exposure to positive reinforcement.
The invention concerns an elastomer system having biocide properties and useful, in particular, for impression, for example, dental impressions. The invention aims at providing an efficient system for destroying microbes, without adversely affecting the crosslinking properties and the mechanical qualities of EVF 2 elastomers. Said system comprises an EVF 2 silicone, preferably SiH/SiVi polyaddition product and a biocide selected among active chlorine precursors, preferably among N-chloramines. The system may include functional additives (silicone fillers, alumina, paraffin, vaseline oil). As for the biocide, it can be provided with an adjuvant using antiseptic quaternary ammonium, even with EDTA-type complexing agents. The invention is useful for impressions in dentistry.
The invention relates to the technical field of microorganisms, and particularly relates to sulfur cinnabarinum and application thereof in treating digestive tract ulcer and colitis. The sulfur bacteria vermilion (Laetiporus Sulphureus) ttys-997 of the invention has been preserved in the common microorganism center of China general microbiological culture Collection center in 12-3.2020, is classified and named as sulfur bacteria vermilion (Laetiporus Sulphureus), and the preservation number is as follows: cgmccno.21084, storage address: the institute of microbiology, national academy of sciences No. 3, Xilu No. 1, Beijing, Chaoyang, Beijing. The invention relates to a sulfur vermilion ttys-997, which belongs to pure natural green edible fungi and is a precious large fungus with rich nutrition and dual purposes of food and medicine. The liquid preparation prepared by fermenting the bacillus subtilis has obvious treatment effect on digestive tract ulcer and colitis.
The invention discloses an externally-applied patch of for local points to treat gynecologic pelvic inflammatory diseases. A conventional plaster matrix and traditional Chinese herbs are used as raw materials, the applied traditional Chinese herbs include dandelion, artemis sphaerocephala krasch, radices trichosanthis, rheum officinale, turmeric, bombyx batryticatus, cortex phellodendri, radix scutellariae, radix bupleuri, olibanum, myrrh, borneol, radix paeoniae rubra, mirabilite, mentha haplocalyx, radix angelicae and oldenlandia diffusa. The raw materials are crushed, concentrated and extracted to prepare extract, far infrared ceramic powder, magnetic powder and nano silver powder are added and mixed with the plaster matrix in a coating way, and thus cream paste is prepared. Since the patch is prepared with natural traditional Chinese herbs, far infrared ceramic powder, magnetic powder and nano silver powder, the patch has good effects of activating main and collateral channels, promoting blood circulation, removing stasis, eliminating inflammation, swelling and pains, and treating gynecological acute and chronic pelvic inflammatory diseases, masses, dysmenorrheal and cervical erosion. Due to the mechanical stimulation of points and direct leading of the pharmaceutical ingredients into focuses by the far infrared ceramic powder, the magnetic powder and the nano silver powder through the main and collateral channels, the inflammation dissipation and absorption can be promoted to achieve curing effects. The plaster also has good effects on treatment of cervical spondylosis, lumbar spine and other surgical inflammation.
In addition to the after school lifestyle classes, participants will receive group Interactive Guided ImagerySM (IGI) delivered once weekly for 12 weeks as an after school class of \~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as "Council", a group communication process used by many indigenous and other cultures. Participants in this arm will receive stress reduction IGI for 4 wks, plus 8 weekly sessions with IGI content designed to promote physical activity and healthy eating.
BACKGROUND: The cardiometabolic index (CMI), encompassing obesity and lipid metrics, is potentially linked to kidney stone prevalence in diabetic patients. However, studies on this association are sparse. This research evaluates CMI's impact on kidney stone occurrence in this group.
METHODS: Utilizing data from the 2007-2018 National Health and Nutrition Examination Survey, we explored the relationship between CMI and kidney stones in diabetic patients through multivariate logistic regression, generalized additive models, and smoothed curve fitting. Robustness checks included subgroup analyses and propensity score matching (PSM).
RESULTS: This study comprised 2714 participants in total, where the prevalence of kidney stones was found to be 16.82%. Using weighted multivariate logistic regression and fully adjusted models, it was revealed that elevated CMI levels are positively associated with an increased likelihood of developing kidney stones (OR = 1.17, 95% CI: 1.06, 1.30). Smooth curve fitting demonstrated that there was no non-linear relationship between CMI and kidney stones (log-likelihood ratio test P = 0.236). Subgroup analyses and interactions indicated that the association between CMI and kidney stone prevalence was notably stronger in individuals who were living with a partner /married and had a poverty income ratio (PIR) of 1.5 to less than 3.5 (P for interaction < 0.05). propensity score matching (PSM) further verified the robustness of our results.
CONCLUSION: Elevated CMI correlates with greater kidney stone prevalence in diabetic individuals, particularly those married or living with a partner and within certain economic statuses. This study supports the hypothesis linking CMI and kidney stones in U.S. diabetic population, suggesting a target demographic for preventive strategies.
The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
This is an open-label (identity of assigned study drug will be known) study to evaluate the safety, pharmacokinetics (study of what the body does to a drug), pharmacodynamics (study of what a drug does to the body), and anti-tumor activities of STM 434 (an inhibitor of activin A) in patients with ovarian cancer and other advanced solid tumors. The study will be conducted in 3 phases (Part 1, Part 2 and Part 3). In the first part of the study (Part 1), which will enroll patients with multiple solid tumor types, the maximum tolerated dose (MTD) of STM 434 will be determined for use in the second and third parts of the study (Parts 2 and 3). In the second part (Part 2), which will enroll patients with ovarian cancer, STM 434 will be administered alone, and in the third part (Part 3), which will enroll patients with ovarian cancer, STM 434 will be given together with a chemotherapy called liposomal doxorubicin. Doses of STM 434 (starting at 0.25 mg/kg up to a maximum of 4 mg/kg) will be taken on one of three dosing schedules to determine the MTD. Patients will continue taking STM 434 until their tumor progresses. Serial blood samples will be collected for pharmacokinetic and pharmacodynamic testing and safety will be monitored throughout the study.
Therefore, the aim of this study was to analyse the effect of different degrees of instability on power and speed of execution in the bench press exercise. For the design of this quasi-experimental research, with an ad hoc protocol, an intersubject comparison was used in 5 different conditions. 20 male participants were grouped into two groups based on their previous experience with unstable training and volunteered for this study. Expert group (n= 10; 23.70 ± 4.30 years; 81.40 ± 9.67 kg; 179.50 ± 8.95 cm; 3.5 ± 4.10 years of strength training experience; 9 ± 10.60 months of unstable training experience) Novice group (n= 10; 25.60 ± 6.50 years; 77.80 ± 4.44 kg; 176.40 ± 2.80 cm; 3.40 ± 1.96 years of strength training experience; 0.90 ± 0.99 months of unstable training experience). Subjects with no experience in training with unstable loads (having implemented unstable loads in their training at some point) or current or recent injuries (within the last 6 months) that caused them to alter their normal physical activity were excluded from this study. This study was in accordance with the Declaration of Helsinki (2013). All participants gave written informed consent prior to the study.

Subjects performed the bench press exercise by assessing mean propulsive velocity and power with 3 different loads for each of the unstable situations: light (40% of 1RM), moderate (60% of 1RM) and high (80% of 1RM). In a familiarisation session, subjects performed the relative loads with each condition to determine their strength-velocity profiles and their optimal work percentages. In addition, an incremental load test was performed to determine the 1RM of each of the participants to determine the external load for each load percentage in each of the subjects.
PROBLEM TO BE SOLVED: To obtain the subject preparation not causing a photoallergy even in use in high concentration, having excellent skin lightening effect, of preventing and treating stain and freckles by including a specific cyclic compound. SOLUTION: This preparation comprises a cyclic compound of formula I [X is a connecting group; Y is any of connecting groups of formula II and formula III (J is a substituent group on a benzene ring; (m) is 1-5; G is a connecting group; Q is a condensed or substituted ring structure) or the like; (n) is a natural number] (with the proviso that cycloheptadiene of formula IV is omitted). Preferably, 0.0001-20 wt.% of the compound or its salt is contained in the objective preparation. The preparation is properly mixed, if required, with a component useful for a common cosmetic, quasi-drug, medicine, or the like, such as a skin lightening agent, humectant, oily component, or the like. The preparation is combined with a well-known skin lightening agent, antioxidant (e.g. ascorbic acid, an ascorbic acid derivative, a vitamin E derivative, or the like) to raise a skin lightening effect.
Symptomatic hand osteoarthritis (HOA) is estimated to affect 15.9% of women and 8.2% of men in the general population. Since no therapy can completely cure HOA at present, alternative effective therapies are needed. Acupuncture has been an effective treatment to alleviate pain and improve joint motion for patients with knee osteoarthritis according to a considerable amount of research. It is not surprised that acupuncture is effective in treating HOA in clinical practice considering the similar pathogenesis HOA shared with knee osteoarthritis. However, the research on the effects of acupuncture in patients with HOA is very limited. The present study aims to evaluate the efficacy and safety of acupuncture for HOA.
As many as 80% of low-grade gliomas (LGGs) present with seizures, negatively impacting quality of life. While seizures are associated with gliomas regardless of grade, the importance of minimizing impact of seizures for patients with low grade tumors cannot be understated given the prolonged survival period in this population. The objective of this systematic review and meta-analysis was to summarize existing literature and identify factors associated with post-operative seizure control (defined as Engel I classification) in patients with LGGs, with a focus on pre-operative factors. Patient data extracted include tumor location and histology, pre-operative anti-seizure medication use, extent of resection (EOR), adjuvant treatment, pre-operative seizure type, duration, and frequency, and post-operative Engel classification. A random-effects model was used to calculate the effects of EOR, pre-operative seizure duration, adjuvant radiation, and adjuvant chemotherapy on post-operative seizure control. The effect of tumor location and histology on post-operative Engel I classification was determined using contingency analyses. Thirteen studies including 1628 patients with seizures were included in the systematic review. On meta-analyses, Engel I classification was associated with pre-operative seizure type (OR = 0.79 (0.63-0.99), p = 0.0385, focal versus generalized), frontal lobe LGGs (OR = 1.5 (1.1-2.0), p = 0.0195), and EOR (OR (95% CI) = 4.5 (2.3-6.7), p < 0.0001 gross-total versus subtotal). Pre-operative seizure duration less than one year, adjuvant radiation, adjuvant chemotherapy, and tumor histology were not associated with achieving Engel I classification. In addition to the known effects of EOR, Engel I classification is less likely to be achieved in patients with focal pre-operative seizures and more likely to be achieved in patients with frontal lobe LGGs.